Impact on Renal Function of Rosuvastatin Preload Prior to Elective Percutaneous Coronary Intervention in Chronic Statin Users

Oliveira, Maurício; Martins, Kleber Bomfim Araujo; Costa, J. Ribamar; Abizaid, Alexandre; Stadler, Jackson; Mattos, Luiz Alberto; Chamié, Daniel; Siqueira, Dimytri; Costa, Ricardo; Staico, Rodolfo; Feres, Fausto; Sousa, Amanda G.M.R.; Sousa, J. Eduardo

doi:10.1016/s0104-1843(12)50051-2

Cited by 5 publications

(13 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…37 Our studies included newer studies that used lower volume of contrast media, which caused less tubular toxicities. [16][17][18][19][20]27 Therefore, our meta-analysis successfully reveals the benefit of statins for the prevention of CIAKI.…”

Section: Discussionmentioning

confidence: 87%

“…Jo et al 22 Zhou et al 23 Wang et al 24 Xinwei et al 14 Toso et al 25 Country Ozhan et al 26 Acikel et al 28 Patti et al 18 de Oliveira et al 27 Quintavalle et al 19 Country Turkey Li et al 20 Han et al 16 Leoncini et al 16 Country Statins for prevention of contrast-induced acute kidney injury 5 rather than a fixed-effect model. Statistical heterogeneity was assessed using the Cochran's Q test.…”

Section: Discussionmentioning

confidence: 99%

“…[12][13][14][15][16][17][18][19][20] Conversely, a few studies showed no significant beneficial effect of statins for prevention of CIAKI. [21][22][23][24][25][26][27][28] To assess whether statins had beneficial effects on prevention of CIAKI, we performed this meta-analysis to investigate the effect of statins on the incidence of CIAKI between statin and control groups.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Periprocedural effects of statins on the incidence of contrast-induced acute kidney injury: a systematic review and meta-analysis of randomized controlled trials

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 87%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Periprocedural effects of statins on the incidence of contrast-induced acute kidney injury: a systematic review and meta-analysis of randomized controlled trials

et al. 2015

View full text Add to dashboard Cite

show abstract

“…1) [17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33]. Twenty-seven studies were reviewed in full text.…”

Section: Characteristics Of the Studies Includedmentioning

confidence: 99%

“…The results of risk of bias assessment are presented in Figure S1 ( [28] Han et al [33] Jo et al [17] Leoncini et al [32] Li et al [29] Patti et al [26] Quintavalle et al [30] Toso et al [23] Özhan et al [ [27] Chen and Su [18] De Oliveira et al [28] Han et al [33] Jo et al [17] Li et al [29] Lu et al [25] Patti et al [26] Toso et al [23] Özhan et al [22] Han et al [33] Jo et al [17] Leoncini et al [32] Patti et al [26] Toso et al [23] Total (95% CI) Total events Heterogeneity: 2 = 0.00; 2 = 0.41, d.f. = 4 (P = 0.98); I 2 = 0% Test for overall effect: Z = 1.80 (P = 0.07) provided insufficient information on the sequence generation and allocation concealment process, because of which they had an unclear risk of selection bias.…”

Section: Risk Of Bias Assessmentmentioning

confidence: 99%

Effect of statins in preventing contrast-induced nephropathy

Xie

Ye²,

Shan³

et al. 2014

Coronary Artery Disease

View full text Add to dashboard Cite

show abstract

Efficacy of short-term moderate or high-dose rosuvastatin in preventing contrast-induced nephropathy

Liang

Yang²,

Fu³

2017

Medicine

View full text Add to dashboard Cite

Background:The prophylactic efficacy of statin pretreatment for the prevention of contrast-induced nephropathy (CIN) in patients undergoing coronary angiography (CAG) or percutaneous coronary intervention (PCI) remains controversial. The aim of the study was to perform a meta-analysis of randomized controlled trials (RCTs) to assess the effectiveness of short-term moderate or high-dose rosuvastatin pretreatment in preventing CIN.Methods:We included RCTs comparing short-term moderate or high-dose rosuvastatin treatment versus low-dose rosuvastatin treatment or placebo for preventing CIN. The primary endpoint was the incidence of CIN within 2 to 5 days after contrast administration, and related-parameters including serum creatinine (SCr), cystatin C (CysC), hypersensitive C-reactive protein (hs-CRP), urine microalbumin (mALB) were also extracted.Results:Fifteen RCTs with a total of 2673 patients were identified and analyzed. Patients who received moderate or high-dose rosuvastatin pretreatment had a 55% lower risk of CIN compared with low-dose rosuvastatin pretreatment or placebo group based on a fixed effect model (RR = 0.45, 95% CI 0.35–0.58, P < .0001). The benefit of moderate or high-dose rosuvastatin was consistent in both comparisons with low-dose rosuvastatin (RR = 0.40, 95% CI 0.27–0.59, P < .0001) or placebo (RR = 0.45, 95% CI 0.35–0.58, P < .0001). And moderate (20 mg) or high dose (≥40 mg) rosuvastatin significantly reduced the incidence of CIN compared with the control (RR = 0.39, 95% CI 0.29–0.54, P < .0001, RR = 0.56, 95% CI 0.37–0.85, P = .006, respectively). Subgroup analysis showed that moderate or high-dose rosuvastatin pretreatment could decrease the incidence of CIN in patients with chronic kidney disease (CKD) (RR = 0.53, 95% CI 0.30–0.93, P = .03) or diabetes mellitus (DM) (RR = 0.51, 95% CI 0.31–0.86, P = .01) or acute coronary syndrome (ACS) patients undergoing PCI (RR = 0.52, 95% CI 0.35–0.76, P = .0009) or in studies which received mean contrast volume ≥110 mL (RR = 0.43, 95% CI 0.32–0.58, P < .0001). The SCr, CysC, hs-CRP, and mALB after the operation in the moderate or high-dose rosuvastatin group were lower than those of low-dose rosuvastatin group.Conclusion:This meta-analysis demonstrated that moderate or high-dose rosuvastatin treatment could reduce the incidence of CIN in patients undergoing CAG or PCI. Moreover, moderate or high-dose rosuvastatin would be beneficial in high-risk patients with CKD or DM or undergoing PCI.

show abstract

Impact on Renal Function of Rosuvastatin Preload Prior to Elective Percutaneous Coronary Intervention in Chronic Statin Users

Cited by 5 publications

References 11 publications

Periprocedural effects of statins on the incidence of contrast-induced acute kidney injury: a systematic review and meta-analysis of randomized controlled trials

Periprocedural effects of statins on the incidence of contrast-induced acute kidney injury: a systematic review and meta-analysis of randomized controlled trials

Effect of statins in preventing contrast-induced nephropathy

Efficacy of short-term moderate or high-dose rosuvastatin in preventing contrast-induced nephropathy

Contact Info

Product

Resources

About